|
| |
IncyteIncyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced management and discovery team. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in healthcare, improve the lives of patients and build significant sustainable value for our shareholders.
We have assembled a competitive and talented drug discovery and development team, which has extensive experience in a number of therapeutic areas. We have active internal drug discovery programs focused on the identification of novel small molecule drugs for oncology, inflammation, HIV and diabetes.
Incyte's corporate headquarters is located in Wilmington, Delaware
| Contact Details: |
| Experimental Station Route 141 & Henry Clay Road Building E336 |
| Wilmington |
| Delaware |
| 19880 |
| United States of America |
| Tel: | 302.498.6700 |
| Fax: | 302.425.2750 |
| Email: | investor@incyte.com |
| WWW: | www.incyte.com/
|
|
Loading...
|
Recent Publications by Incyte: |  |
Combined inhibition of janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
PURPOSE: Deregulation of the Janus kinase-signal transducers and... | 6th November, 2009
| Departments of Applied Technology, Preclinical Biology, In vitro Biology,
| Clin Cancer Res. 2009 Nov 15;15(22):6891-900. Epub 2009 Nov 3.
DOI Direct Link |
Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.
A serendipitous discovery that the metalloprotease binding profile of a... | 2nd September, 2009
| Incyte Corporation, Department of Medicinal Chemistry, Wilmington, DE
| Bioorg Med Chem Lett. 2009 Jul 1;19(13):3525-30. Epub 2009 May 5.
DOI Direct Link |
Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2.
The chemokine receptor 2 (CCR2) directs migration of monocytes and has... | 21st August, 2009
| Department of In Vitro Biology, Incyte Corporation, Wilmington, DE, United
| Biochem Biophys Res Commun. 2009 Sep 18;387(2):251-5. Epub 2009 Jul 1.
DOI Direct Link |
Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.
A novel series of carbamates was discovered as potent and selective HER-2... | 29th July, 2009
| Incyte Corporation, Experimental Station-E336, Route 141 and Henry Clay
| Bioorg Med Chem Lett. 2009 Sep 1;19(17):5037-42. Epub 2009 Jul 25.
DOI Direct Link |
Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities.
Objective: Identification of potential pharmacokinetic drug-drug... | 25th July, 2009
| Incyte Corp, Wilmington, Delaware.
| Psychopharmacol Bull. 2009;42(2):47-63.
|
→View more Incyte research publications. |
Press Releases on Incyte:
|
 |
| New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel |
6th November, 2009 |
MedPredict |
-- Role of other mechanisms, including CTLA4, IL-6, IL-17, JAK, Syk,
TNF/PDE4, BTK, MEK, and S1P.
Companies/Partnerships mentioned in this report include: Abbott, Alder, Amgen/Pfizer,
|
| Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market |
26th October, 2009 |
Decision Resources |
WALTHAM, Mass., Oct. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of
|
| New Report Defines Challenges for New Entrants in Key Rheumatology Markets |
7th April, 2009 |
MedPredict |
MedPredict's Rheumatology Thought Leader Panel Creates a 'Fantasy Formulary' For 2015
SCOTTSDALE, Ariz., April 7 /PRNewswire/ -- MedPredict Market Research, a global provider of
|
| MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development |
23rd January, 2009 |
MedPredict |
SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new reports providing
|
| Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO |
8th September, 2008 |
Zosano Pharma, Inc. |
FREMONT, Calif., Sept. 8 /PRNewswire/ -- Zosano Pharma, Inc., a privately
held pharmaceutical company developing a novel transdermal delivery
technology, today announced that Gail Schulze has
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 24 individuals from Incyte using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 696 times since April 2007, the link to the organisation's website has been followed 78 times Recent Search Terms used to find this page: financial value of incyte database | CCR2 incyte | ccr2 diabetes incyte | incb18424 patent | ccr2 incyte 2009 | incb18424 synthesis Enantioselective | INCB18 | ncb18424 july 2009 | incyte | INCB 18424 pdf | . Search for more companies in Wilmington Search for more companies in Delaware This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Incyte |
